← FDA ENFORCEMENT
D-1074-2023Class II

Central Admixture Pharmacy Services Inc

Recalling firm
Central Admixture Pharmacy Services Inc
Product type
Drug
Status
Terminated
Report date
2023-08-09
Distribution
Nationwide in the USA
Firm state
CA
Product quantity
9,517 syringes
Initiated by
Voluntary: Firm initiated
SPEQ quality domain
Environmental Monitoring
Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Product description

lidocaine 2%, 100 mg /5 mL, (20 mg/mL), 5 mL Syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-6006-1

Code / lot info

Lot: 17-271076, Exp. 7/24/2023; 17-271132, 17-271165, Exp. 7/25/2023; 17-271230, 17-271250, Exp. 7/26/2023; 17-271508, Exp. 7/31/2023; 17-271595, 17-271604, Exp. 8/1/2023; 17-271658, Exp. 8/2/2023; 17-271764, Exp. 8/3/2023; 17-271826, Exp. 8/6/2023; 17-271972, Exp. 8/8/2023; 17-272052, 17-272057, Exp. 8/9/2023; 17-272139, Exp. 8/10/2023; 17-272258, Exp. 8/14/2023; 17-272470, Exp. 8/16/2023; 17-272690, Exp. 8/20/2023; 17-272822, Exp. 8/23/2023; 17-273054, 17-273065, Exp. 8/28/2023; 17-273423, Exp. 9/2/2023; 17-273771, Exp. 9/7/2023.

Other recalls SPEQ maps to Environmental Monitoring
2026-07-22Class IArgon Medical Devices, Inc2026-07-22Class IIOlympus Corporation of the Americas2026-07-22Class IIChiesi USA, Inc.2026-07-22Class IICareFusion 213, LLC
See all Environmental Monitoring recalls →

Data: U.S. FDA openFDA enforcement API. Recall details are as reported by the FDA. The quality-domain mapping and severity are a SPEQ editorial interpretation of the recall reason, not an official FDA classification.